Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor

Author： He Kan  

Publisher： Springer Publishing Company

ISSN： 0378-7966

Source： European Journal of Drug Metabolism and Pharmacokinetics, Vol.36, Iss.3, 2011-09, pp. : 129-139

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics and Pharmacodynamics of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor

By  

Current Clinical Pharmacology, Vol. 9, Iss. 1, 2014-02 ,pp. : 75-83

Bentham Science Publishers

Access to resources Recommend Favorite

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - in Patients Undergoing Major Orthopaedic Surgery

By Mueck Wolfgang  

Clinical Pharmacokinetics, Vol. 47, Iss. 3, 2008-01 ,pp. : 203-216

Adis International

Access to resources Recommend Favorite

Clinical Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Darexaban, an Oral Direct Factor Xa Inhibitor, in Healthy Elderly Japanese Subjects

By  

Clinical Pharmacology In Drug Development, Vol. 2, Iss. 4, 2013-10 ,pp. : 328-335

John Wiley & Sons Inc

Access to resources Recommend Favorite

Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict

By Carreiro Jennifer   Ansell Jack  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 12, 2008-12 ,pp. : 1937-1945

Informa Healthcare

Access to resources Recommend Favorite

Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development

By Eriksson Bengt I.  

Clinical Pharmacokinetics, Vol. 48, Iss. 1, 2009-01 ,pp. : 1-22

Adis International

Access to resources Recommend Favorite